Treatment Strategy: Role of Enfuvirtide in Managing Treatment-Limiting Side Effects | Zendy

Christos Tsoukas | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment Strategy: Role of Enfuvirtide in Managing Treatment-Limiting Side Effects

Author(s) -

Christos Tsoukas

Publication year - 2007

Publication title -

canadian journal of infectious diseases and medical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.634

H-Index - 38

eISSN - 1918-1493

pISSN - 1712-9532

DOI - 10.1155/2007/198172

Subject(s) - enfuvirtide , limiting , medicine , intensive care medicine , pharmacology , immunology , antibody , gp41 , engineering , epitope , mechanical engineering

Side effects can limit the options available to physicians for the treatment of HIV infection. Management of these side effects is essential, to avoid cessation of treatment. The entry inhibitor enfuvirtide can be useful as one of three active agents in an HIV treatment regimen as a way to both reduce treatment-limiting side effects and provide an efficacious agent for viral control. In the present case, the patient had a problematic and lengthy treatment history, with numerous concomitant conditions. His latest regimen, which includes an agent in a new drug class (enfuvirtide), has maintained HIV suppression while minimizing toxicity

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research